Table 1.
GH signaling inhibitors
| Strategy/drug name | Target | Company |
|---|---|---|
| SSTN receptor ligands | ||
| Octreotide LAR42,43 | GH secretion | Novartis; clinical use |
| Lanreotide autogel42,43 | GH secretion | Ipsen; clinical use |
| Pasireotide LAR42,43 | GH secretion | Novartis; clinical use |
| Octreolin42,43 | GH secretion | Chiasma; clinical development |
| Intravail Octreotide ProTek42,43 | GH secretion | Aegis; clinical use |
| Somatoprim (DG3173)42,43 | GH secretion | Aspireo; clinical development |
| Dopamine agonist | ||
| Cabergoline42,43 | PRL/GH secretion | Par Pharmaceutical; clinical use |
| GHRH antagonists111 | GH secretion | Preclinical development |
| GH analogs | ||
| Pegvisomant/B20366,114 | GHR | Pfizer; clinical use |
| GH-G120R118 | GHR/PRLR | |
| Fusion proteins | ||
| Antagonist–GHBP fusion128 | GHR | Asterion Ltd.; clinical development |
| Antisense oligonucleotide | ||
| ATL1103 (Atesidorsen)132 | GHR | Antisense Therapeutics Ltd.; clinical development |
| Anti-GHR antibody | ||
| Anti-GHRcyt-mAb133,137 | GHR | |
| GF185136 | GHR | |
| RN172135 | GHR | Pfizer; preclinical |
| CG-86134 | Ghr (porcine) | |
| Small molecule compound | ||
| BVT-A138 | Unknown | |
| GH signaling pathway inhibitors | ||
| JAK-STAT, MAPK, PI3K/AKT/mTOR140–144 | ||
GHR growth hormone receptor, SSTN somatostatin, PRLR prolactin receptor, PRL prolactin, JAK-2 Janus kinase 2, STAT signal transducer and activator of transcription, MAPK mitogen-activated protein kinase, PI3K/AKT/mTOR phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin